Contrasting Neurogene (NGNE) & The Competition

Neurogene (NASDAQ:NGNE) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Neurogene to related companies based on the strength of its valuation, institutional ownership, risk, dividends, analyst recommendations, earnings and profitability.

Profitability

This table compares Neurogene and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Neurogene Competitors	-12,359.35%	-203.09%	-30.93%

Institutional and Insider Ownership

52.4% of Neurogene shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neurogene and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Neurogene	$930,000.00	-$90.35 million	-5.17
Neurogene Competitors	$698.09 million	$10.43 million	-15.42

Neurogene’s peers have higher revenue and earnings than Neurogene. Neurogene is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Neurogene and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1	0	5	2	3.00
Neurogene Competitors	9846	15129	45501	1589	2.54

Neurogene currently has a consensus target price of $79.57, suggesting a potential upside of 206.04%. As a group, “Biotechnology” companies have a potential upside of 98.12%. Given Neurogene’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Neurogene is more favorable than its peers.

Volatility and Risk

Neurogene has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Neurogene’s peers have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Summary

Neurogene beats its peers on 8 of the 13 factors compared.

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.